UNLEARN

AI-powered RCTs for the 21st century

unlearn.ai

TwinRCTs leverage trial participants' AI-generated digital twins to run:

Faster trials

That maintain power with smaller control groups

Highly powered trials

Without increasing sample size

Solutions

SOLUTION 1

Core

- Digital twins of the participants in your study
- A cloud-hosted digital twin dashboard

SOLUTION 2

Premium

- Digital twins of the participants in your study
- A cloud-hosted digital twin dashboard
- </> Code for TwinRCT trial design and analysis
- Statistical and regulatory support

SOLUTION 3

Custom

- Digital twins of the participants in your study
- A cloud-hosted digital twin dashboard
- </> Code for TwinRCT trial design and analysis
- Statistical and regulatory support
- Customized DTG or a Customized Analysis Plan

Digital twins of individual clinical trial participants

Unlearn invents, trains, and deploys AI models that produce accurate, comprehensive forecasts of a patient's future clinical outcomes—which we call their digital twin.

Here's an example.

Forecast →

TwinRCT

- → Create a digital twin for each participant in a randomized study regardless of treatment group.
- → Use their digital twins to forecast their prognoses as if they were assigned to the control group.
- → Adjust for the forecast prognoses during analysis.





Better forecasts directly translate into TwinRCTs with higher power or smaller control groups

World Leading Regulatory Science

TwinRCTs are randomized controlled trials that use our regulatory qualified PROCOVA framework to incorporate participants' digital twins into trials to deliver more power with smaller control groups.

RCT



TwinRCT

We are paving the regulatory pathway for AI-powered clinical research

"FDA recommends that sponsors adjust for covariates that are anticipated to be most strongly associated with the outcome of interest...it may be useful to use previous studies to select prognostic covariates or form prognostic indices."

FDA Guidance on Covariate Adjustment

MAY 2023

"CHMP qualifies PROCOVA and that the proposed procedures could enable increases in power and/or decreases in sample size in phase 2 and 3 clinical trials with continuous outcomes."

EMA Qualification Opinion for PROCOVA

SEPTEMBER 2022

Innovative research on generative AI

Our probabilistic neural networks predict potential health outcomes for individual patients, providing an unrivaled view into the entire probability distribution of outcomes at the individual level.



Busting digital twin myths

01

A patient's digital twin is computationally created with generative AI; it is not a matched patient from an external cohort.

02

A patient's digital twin provides a probabilistic forecast of their specific health outcomes, it can't be used like data from a new patient.

03

Clinical trials that incorporate participants' digital twins are randomized with concurrent control groups; they do not use synthetic control groups.

04

TwinRCTs use a regulatory-qualified framework to incorporate participants' digital twins; their suitability for phase 2&3 trials depends on the context-of-use rather than the inner-workings of the AI.

Join us at the frontier of AI in medicine

Current Indications

Alzheimer’s Disease (AD)
Amyotrophic Lateral Sclerosis (ALS)
Frontotemporal Dementia (FTD)
Huntington’s Disease (HD)

Under Active Development

Parkinson’s Disease (PD)
Ulcerative Colitis/Crohn’s (IBD)
Obesity
Type 2 Diabetes
Rheumatoid Arthritis
Psoriasis
Hypertension
Dyslipidemia
Multiple sclerosis (MS)
Coronary Artery Disease

We collaborate with pharmaceutical and biotech companies to design AI-powered clinical trials that provide higher precision and shorter enrollment times.

UNLEARN

unlearn.ai